LÄKEMEDELSVERKET
MEDICAL PRODUCTS AGENCY

Public Assessment Report
Scientific discussion

Telmisartan Jubilant
(telmisartan)

SE/H/1291/01-03/DC

This module reflects the scientific discussion for the approval of Telmisartan Jubilant. The procedure was finalised on 2013-09-19. For information on changes after this date please refer to the module 'Update'.

Postadress/Postal address: P.O. Box 26, SE-751 03 Uppsala, SWEDEN
Besöksadress/Visiting address: Dag Hammarskjölds väg 42, Uppsala
Telefon/Phone: +46 (0)18 17 46 00 Fax: +46 (0)18 54 85 66
Internet: www.mpa.se E-mail: registrator@mpa.se

I. INTRODUCTION

The application for Telmisartan Jubilant, 20, 40 and 80 mg, tablets, is a generic application made according to Article 10(1) of Directive 2001/83/EC. The applicant, Jubilant Pharmaceuticals nv, applies through the Decentralised Procedure with Sweden acting as reference member state (RMS) and BG, DE, DK, MT, NL and UK as concerned member states (CMS).

The reference medicinal product chosen for the purposes of establishing the expiry of the data protection period is Micardis, 20 mg, tablets authorised in the community since 1998, with Boehringer Ingelheim International GmbH as marketing authorisation holder. The reference product used in the bioequivalence study is Micardis, 80 mg, tablets from Belgium with Boehringer Ingelheim International GmbH as marketing authorisation holder.

For approved indications, see the Summary of Product Characteristics.

II. QUALITY ASPECTS

II.1 Introduction

Telmisartan Jubilant is presented in the form of tablets containing 20 mg, 40 mg or 80 mg of telmisartan. The excipients are povidone, meglumine, sodium hydroxide, mannitol and magnesium stearate. The tablets are packed in aluminium blister.

II.2 Drug Substance

Telmisartan has a monograph in the Ph Eur.

Telmisartan is a white or slightly yellowish crystalline powder which is practically insoluble in water. The structure of telmisartan has been adequately proven and its physico-chemical properties sufficiently described. The route of synthesis has been adequately described and satisfactory specifications have been provided for starting materials, reagents and solvents.

The active substance specification includes relevant tests and the limits for impurities/degradation products have been justified. The analytical methods applied are suitably described and validated.

Stability studies under ICH conditions have been conducted and the data provided are sufficient to confirm the retest period.

II.3 Medicinal Product

Telmisartan Jubilant tablets are formulated using excipients described in the current Ph Eur. All raw materials used in the product has demonstrated compliance with Commission Directive 2003/63/EC and the NfG on Minimising the risk of transmitting Animal Spongiform Encephalopathy Agents via human and veterinary medicinal products (EMEA/410/01).

The product development has taken into consideration the physico-chemical characteristics of the active substance, such as poor aqueous solubility, polymorphism and stability.

The manufacturing process has been sufficiently described and critical steps identified. Results from the process validation studies confirm that the process is under control and ensure both batch to batch reproducibility and compliance with the product specification.

The tests and limits in the specification are considered appropriate to control the quality of the finished product in relation to its intended purpose.

Stability studies under ICH conditions have been performed and data presented support the shelf life claimed in the SPC, with no special storage precautions.

III. NON-CLINICAL ASPECTS

III.1 Discussion on the non-clinical aspects

Since this product has been shown to be essentially similar and refer to a product approved based on a full application with regard to preclinical data, no further such data have been submitted or are considered necessary.

IV. CLINICAL ASPECTS

IV.1 Pharmacokinetics

Bioequivalence was evaluated in one single-dose, two-treatment, four-period, two-sequence, four-way crossover study conducted in 60 healthy volunteers, comparing Telmisartan, 80 mg, tablet with Micardis, 80 mg, tablet under fasting conditions. The study was conducted at Jubilant Clinsys Limited, Uttar Pradesh, India between 23rd January 2012 and 11th March 2012. Blood samples were collected pre-dose and up to 120 hours post-dose. The study design is considered acceptable. Plasma concentrations of telmisartan were determined with an adequately validated LC-MS/MS method. For AUC_{0-t} and C_{max} the 90% confidence interval for the ratio of the test and reference products fell within the conventional acceptance range of 80.00-125.00% and bioequivalence was demonstrated. From a pharmacokinetic point of view, absence of studies with the lower strengths 20 mg and 40 mg is acceptable, as the plasma exposure of telmisartan increases more than proportional to dose in the therapeutic dose range.

IV.2 Discussion on the clinical aspects

Since this product has been shown to be essentially similar and refer to a product approved based on a full application with regard to clinical efficacy/safety data, no further such data have been submitted or are considered necessary.

V. OVERALL CONCLUSION, BENEFIT/RISK ASSESSMENT AND RECOMMENDATION

User consultation
The package leaflet has been evaluated via a user consultation study in accordance with the requirements of Articles 59(3) and 61(1) of Directive 2001/83/EC. The language used for the purpose of user testing the PIL was English.
The results show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

The results of the conducted bioequivalence study can be extrapolated to the lower strengths of 20 and 40 mg since the criteria for biowaiver for additional strengths are fulfilled according to the Guideline on the Investigation of Bioequivalence.

The risk/benefit ratio is considered positive and Telmisartan Jubilant, 20, 40 and 80 mg, tablets, is recommended for approval.

VI. APPROVAL

The decentralised procedure for Telmisartan Jubilant, 20, 40 and 80 mg, tablets was successfully finalised on 2013-09-19.

LÄKEMEDELSVERKET
MEDICAL PRODUCTS AGENCY

Public Assessment Report – Update

Scope	Procedure number	Product Information affected	Date of start of the procedure	Date of end of procedure	Approval/ non approval	Assessment report attached
						Y/N (version)

Postadress/Postal address: P.O. Box 26, SE-751 03 Uppsala, SWEDEN
Besöksadress/Visiting address: Dag Hammarskjölds väg 42, Uppsala
Telefon/Phone: +46 (0)18 17 46 00 Fax: +46 (0)18 54 85 66
Internet: www.mpa.se E-mail: registrator@mpa.se